Sublingual Immunotherapy: Allergy Drops and Tablets

Separate FDA-approved tablets from custom allergy drops

Sublingual immunotherapy places an allergen under the tongue, but products are not interchangeable. In the United States, FDA-approved tablets are available for specific grass, ragweed, and dust-mite allergies and have product-specific ages, schedules, contraindications, boxed warnings, and prescribing information. Liquid allergy drops compounded from extract are used off label and have not gone through the same FDA approval process for sublingual use. Evidence, dosing, cost, and insurance treatment should be discussed separately.

Ask the clinician to name the exact product, allergen, regulatory status, and evidence for the patient’s sensitization. A broad claim that drops treat everything does not establish that a mixture or dose has been studied. FDA-approved tablets use standardized products and generally one targeted allergen category. The decision should connect a compatible symptom season or year-round dust-mite exposure with focused testing and a realistic treatment goal.

• Exact allergen and whether it matches the patient’s symptom pattern.
• FDA-approved tablet or off-label liquid formulation.
• Age range, contraindications, first-dose observation, and epinephrine requirement.
• Expected start date, daily schedule, treatment duration, and insurance status.

Related care: Treatments. Places SLIT beside other allergy treatment options.

Confirm candidacy and asthma control before the first dose

A positive allergy test alone is not enough. The clinician reviews allergic rhinitis symptoms, exposure, other treatments, asthma, swallowing or esophageal disease, medications, pregnancy considerations, and ability to manage a reaction at home. Severe, unstable, or uncontrolled asthma can increase risk and may make treatment inappropriate. For FDA-approved SLIT tablets, a history of eosinophilic esophagitis is a contraindication rather than simply a background risk factor.

The first tablet dose is administered in a healthcare setting with observation according to the product labeling. Training includes placing the tablet correctly, what not to eat or drink immediately afterward, expected local mouth or throat symptoms, missed doses, and when to stop. FDA-approved tablet labeling requires the prescriber to prescribe auto-injectable epinephrine and instruct the patient in its use. Do not take the first dose at home because the packaging was already dispensed.

Related care: Sublingual immunotherapy. Provides the treatment-specific candidacy, dosing, and safety pathway.

Plan daily home dosing and interruptions in writing

SLIT works through repeated dosing, not occasional use when symptoms are bad. Seasonal tablets may begin weeks or months before the relevant pollen season, while dust-mite treatment is generally year-round under its label. Put dosing, refills, travel storage, and follow-up into a calendar. Use the exact tablet; splitting, combining, or substituting products can change dose and safety.

Ask what to do after a missed dose, several missed days, dental surgery, mouth ulcer, fever, asthma flare, or a new swallowing symptom. Do not double a dose or restart after a prolonged interruption without instructions. Children need consistent adult supervision. Record reactions with timing and treatment so the prescriber can distinguish expected early local symptoms from a pattern that requires adjustment or discontinuation.

Recognize when a local mouth symptom is becoming a safety issue

Itching or mild swelling in the mouth can occur early, but rapidly progressive throat swelling, trouble breathing, voice change, faintness, widespread hives, or severe gastrointestinal symptoms can indicate a systemic reaction. Follow the emergency plan, use epinephrine when directed, and call 911. Antihistamine should not delay epinephrine for anaphylaxis. The tablet is not a rescue treatment for current allergy symptoms.

Persistent chest discomfort, food sticking, painful swallowing, or increasing difficulty swallowing should be reported promptly because eosinophilic esophagitis is a concern with allergen immunotherapy tablets. Significant or escalating local reactions also deserve review. Do not conceal symptoms with repeated medication just to continue dosing. The prescriber needs the unmasked pattern to decide whether treatment remains safe.

Compare tablets with shots using the allergens and routine, not convenience alone

Allergy shots can address a clinician-selected set of relevant allergens but require build-up and maintenance injections with observation in a medical setting. Approved SLIT tablets target limited allergen categories and shift most dosing to the home after the supervised first dose. The options differ in schedule, local and systemic reactions, evidence for each allergen, cost, insurance, travel, and the patient’s ability to follow daily treatment.

Set measurable goals such as symptom days, medication use, sleep, activity, and seasonal impairment, then review them on schedule. Treatment commonly continues for years, so adherence and burden matter. If symptoms remain uncontrolled, confirm diagnosis, exposure, technique, and adherence before assuming failure. A direct efficacy comparison is not simple because products and patient selection differ; the best choice is the one supported for the relevant allergen and feasible to complete safely.

Before switching methods, document what actually failed: the allergen did not match the symptom pattern, daily adherence was unrealistic, local reactions limited dosing, office visits were not feasible, or symptoms persisted despite correct use. Review any new asthma, mouth, swallowing, or medication history because candidacy can change over time. A switch is a new treatment decision with its own first-dose, observation, emergency, and interruption rules; it is not a simple refill of the previous immunotherapy in another form. Plan refills before travel or pollen season, and contact the prescriber rather than substituting a different allergen tablet or another person’s product.